Travere Therapeutics (TVTX) Short-Term Debt issuances (2014)
Travere Therapeutics (TVTX) posted Short-Term Debt issuances of -$42.4 million for Q4 2014, down 1272.27% on a QoQ basis from $3.6 million in Q3 2014.
Travere Therapeutics (TVTX) Short-Term Debt issuances (2014) Analysis & Trends
Travere Therapeutics' Short-Term Debt issuances history runs 1 years deep, the most recent figure standing at -$42.4 million for Q4 2014.
- Quarterly Short-Term Debt issuances changed N/A year-over-year to -$42.4 million in Q4 2014, while the trailing twelve-month figure through Dec 2016 was -$38.8 million (changed N/A YoY) and the FY2015 annual result came in at $45.0 million, changed N/A from the prior year.
- Short-Term Debt issuances was -$42.4 million for Q4 2014 at Travere Therapeutics, down from $3.6 million in the prior quarter.
- Across five years, Short-Term Debt issuances topped out at $3.6 million in Q3 2014 and bottomed at -$42.4 million in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 58.20 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | -42.37 Mn |
| Dec 31, 2014 | -42.37 Mn |
| Sep 30, 2014 | 3.61 Mn |
| Sep 30, 2014 | 3.61 Mn |